MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2016.742 MCO-0-0-742 Articles Combined detection of liver stiffness and C-reactive protein in patients with hepatitis B virus-related liver cirrhosis, with and without hepatocellular carcinoma LIUXIAO-YAN 1 * MALI-NA 1 * YANTING-TING 2 * LUZHEN-HUI 3 * TANGYUAN-YUAN 1 * LUOXIA 1 * DINGXIANG-CHUN 1 Department of Infectious Diseases, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China Department of Hepatobiliary Surgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China Correspondence to: Dr Xiang-Chun Ding, Department of Infectious Diseases, General Hospital of Ningxia Medical University, 1160 Shengli Street, Yinchuan, Ningxia 750004, P.R. China, E-mail: 13619511768@163.com

Contributed equally

 04 2016 26 01 2016 4 4 587 590 09062015 07092015 Copyright © 2016, Spandidos Publications 2016

The aim of the present study was to investigate the usefulness of combined detection of liver stiffness (LS) and serum C-reactive protein (CRP) level in patients with hepatitis B virus (HBV)-related liver cirrhosis (LC). A total of 156 cases of previously untreated patients with HBV-related LC were classified into the LC group [LC without hepatocellular carcinoma (HCC)] and the HCC group (LC with HCC). Comparative analyses of LS and serum CRP level were conducted between these two groups. LS values and serum CRP levels were found to be significantly higher in the HCC group compared with those in the LC group (P<0.01). The LS values and serum CRP levels were not significantly different between α-fetoprotein (AFP)-positive and -negative patients. A high LS value was a high-risk factor for HCC in patients with chronic hepatitis B. The CRP-positive rate was significantly higher in the HCC group compared with that in LC group in a subset of patients with high LS values (P<0.01). In conclusion, the combined detection of LS and serum CRP may complement the measurement of AFP in the diagnosis of HBV-related HCC, improve the identification of patients with AFP-negative HCC and help distinguish HCC from LC.

 chronic hepatitis B liver cirrhosis hepatocellular carcinoma FibroScan high-sensitivity C-reactive protein Introduction

Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver (1) and a prevalent malignancy with poor outcome. Approximately 600,000 new cases are diagnosed annually, among which 55% in China (2). The majority of HCC cases (~80%) are associated with chronic hepatitis B virus (HBV) infection-related liver cirrhosis (LC) (3,4). The main treatment used for primary liver cancer is surgery. Asian series have reported a 5-year survival rate of ~70% following resection of HCCs sized <2 cm, while the current 5-year survival rate of advanced liver cancer is ~10%, only marginally better compared with that of pancreatic cancer (5). Therefore, early diagnosis is crucial for improving the survival rate of patients with primary liver cancer. However, due to the lack of effective methods for early diagnosis, only 30–40% of patients with primary liver cancer are timely diagnosed and treated at an early stage. The measurement of α-fetoprotein (AFP) levels is widely used as a surveillance test for HCC (6). Several studies of AFP in HCC surveillance revealed that its sensitivity is estimated at 39–64%, its specificity at 76–91%, its positive predictive value at 9–32% and its negative value at ≤30% (6). The sensitivity, specificity and positive predictive value of ultrasound for HCC have been reported to be 71–78, 90–93 and 14–73%, respectively. Adding ultrasound to AFP measurement in the screening of individuals at higher risk of liver cancer may significantly increase the early diagnosis rate; approximately one-third of the patients may be diagnosed and treated at an early stage. Despite the large number of studies on the immunohistochemistry of HCC, such as AFP-L3, α1,6-fucosyltransferase, glypican-3, Dickkopf-1 and heat shock protein 70 (7), absolute positive and negative markers for HCC are still lacking, and even those characterized by very high sensitivity and specificity do not exhibit universal diagnostic usefulness. Therefore, the diagnosis of HCC at an early stage remains a prerequisite for favorable prognosis.

Liver stiffness measurement (LSM) using transient elastography (TE FibroScan®; Echosens, Paris, France) has been shown to be correlated with liver fibrosis in various chronic liver diseases (8–11). LSM correlates well with the stage of liver fibrosis and may serve as a predictor of HCC development among patients with chronic hepatitis (12–16). It remains questionable whether LSM alone may be applied as a predictive marker of primary liver cancer at the clinical setting. Therefore, it is necessary to identify markers that may be combined with liver stiffness (LS) to improve the prediction of HCC.

C-reactive protein (CRP) is an acute-phase protein synthesized by the liver. Rapid, marked increases in CRP levels occur with inflammation, infection, trauma and tissue necrosis (17–21). Several studies have been performed on the association of CRP with the severity of inflammation in liver disease, such as fatty liver and chronic hepatitis C (22–25). A persistently elevated CRP level following initial treatment is an independent marker of a poor prognosis, and normalization of the CRP level after initial treatment is associated with improved outcome in HCC patients (26–28). As regards the ability of CRP to predict HBV-related HCC, it remains unknown. A total of 156 LC cases with and without HCC were compared in terms of LS and high-sensitivity CPR (hs-CRP), to investigate the potential of combined detection of LS and serum CRP level in the diagnosis of HCC in patients with chronic hepatitis B.

 Patients and methods <sec> <title>Patients

A total of 156 patients with HBV-related LC in our hospital were included in this study. The patients were divided into the LC group (LC without HCC) and the HCC group (LC with HCC). These cases were confirmed by clinical presentation, diagnostic ultrasound imaging and laboratory diagnosis. LC was diagnosed according to the guideline of prevention and treatment for chronic hepatitis B, 2010 version (29); HCC was diagnosed according to the criteria formulated by the Chinese Anti-Cancer Association. All the included patients had not been treated with any hepatoprotective, antifibrotic or antiviral drugs. In addition, 50 healthy individuals, without autoimmune or metabolic diseases, without a history of drug or alcohol abuse or other factors that may cause liver damage, and without hematological diseases, were used as the control group. Patients with conditions likely to affect the serum CRP level, such as acute infections, rheumatoid arthritis, gout, asthma, chronic lung disease, myocardial infarction and stroke, were excluded.

 Parameters LSM

Scanning was performed using transient elastography FibroScan® (Echosens) according to the method described in the manufacturer's instructions. The LS grading criteria were as follows: >17.5 kPa cirrhosis; patients were subgrouped with a 5-kPa interval into 17.5–22.5, 22.6–27.5 and >27.6 kPa groups.

 Serum CRP levels

Measurement was performed using the latex enhanced turbidimetric method with the reagent purchased from Roche Diagnostics GmbH (Mannheim, Germany) using the Roche Modular P800 analyzer. The serum CRP normal reference range was 0–2.87 mg/l, with serum hs-CRP >2.87 mg/l considered as positive.

AFP. The plasma levels of AFP were measured using a commercial ELISA kit (Abbott Laboratories Company, Chicago, IL, USA) in accordance with the manufacturer's instructions. The HCC group was divided into AFP-positive (>20 ng/ml) and -negative (≤20 ng/ml).

 Statistical analysis

The statistical analysis was performed using the SPSS v.17.0 software package (SPSS Inc., Chicago, IL, USA). Quantitative data were analyzed using the independent-samples t-test and expressed as mean ± standard deviation. The count data were analyzed using the χ2 test. P<0.05 was considered to indicate a statistically significant difference. Correlation analyses were conducted using the Pearson's and Spearman's correlation tests.

 Results <sec> <title>Clinical data

A total of 156 cases of previously untreated patients with LC were included, 125 of whom were men and 31 were women (mean age, 38±17.1 years). The patients were divided into the LC group (LC without HCC, n=89) and the HCC group (LC with HCC, n=67). Of the 50 healthy controls, 41 were men and 9 were women (mean age, 38±9.4 years). The LSM values and serum CRP levels were found to be significantly higher in the HCC group compared with those in the LC group (P<0.05 and P<0.01, respectively; Table I).

 Comparisons of LSM values and serum CRP levels in AFP-positive and -negative patients

The HCC group was subdivided into the AFP-positive (AFP >20 ng/ml) and AFP-negative (AFP ≤20 ng/ml) groups. The LSM values and serum CRP levels were not significantly different between AFP-positive and -negative patients (P>0.05, Table II).

 Association of LSM values and serum CRP levels with HCC

The proportional analysis of HCC and CRP positivity rate among 3 stratifications of LSM revealed that a high LSM value was a high-risk factor for HCC. In a subset of patients with LSM values >27.6 kPa, the CRP positivity rate was significantly higher in the HCC group (64.15%) compared with that in the LC group (37.97%) (P<0.01, Table III).

 Discussion

The diagnosis of HCC at an early stage is a prerequisite for improved prognosis. LSM using FibroScan transient elastography has been shown to be correlated with liver fibrosis in various chronic liver diseases. The LSM cut-off value of 17.5 kPa is considered optimal for diagnosing LC (8–11) and the LSM value is useful in predicting HCC (12–16). Among a total of 156 patients with HBV-related cirrhosis, the LSM values were significantly higher in the HCC group (39.72±29.05 kPa) compared with those in the LC group (27.81± 8.46 kPa) (P<0.05). The LSM values were not significantly different between AFP-positive and -negative patients (P>0.05). The cut-off value was set at 17.5 kPa, and patients were subgrouped with a 5-kPa interval into the 17.5–22.5, 22.6–27.5 and >27.6 kPa groups. This subgroup analysis revealed that a high LSM value (>27.6 kPa) was a high-risk factor for HCC, which was consistent with earlier findings, indicating the usefulness of LSM in predicting HCC. Furthermore, it was observed that 59.85% of patients with LSM values of >27.6 kPa did not have HCC. This positive predictive value was significantly lower compared with that of ultrasound combined with AFP. Therefore, it is necessary to identify markers to combine with LS in order to improve the prediction of HCC.

The majority of the cases of HCC are associated with cirrhosis related to chronic hepatitis (1,3,9). CRP is an acute-phase protein synthesized by the liver. Several studies have been performed to determine the association of CRP with the severity of inflammation in liver diseases, such as fatty liver and chronic hepatitis C. A persistently elevated CRP level following initial treatment is an independent marker of a poor prognosis, and normalization of the CRP level after initial treatment is associated with an improved outcome in HCC patients (17–29). We observed that serum CRP levels were significantly higher in the HCC group (30.78±15.17 mg/l) compared with those in the LC group (9.47±19.56 mg/l) (P<0.01), whereas they were not significantly different between AFP-positive and -negative patients (P>0.05). These results may be explained by the fact that AFP-positive HCC patients may have larger tumors and exhibit more severe inflammation due to the invasion of the portal system. The cut-off value for LSM was set at 17.5 kPa, and patients were subgrouped with a 5-kPa interval into 17.5–22.5, 22.6–27.5 and >27.6 kPa groups. Patients with serum CRP levels >2.87 mg/l were defined as positive, whereas those with serum CRP levels <2.87 mg/l were defined as negative. A proportion analysis was performed of HCC and serum CRP positivity rate among the 3 LSM grades. It was demonstrated that a high LSM value was a high-risk factor for HCC. In a subset of patients with LSM values >27.6 kPa, the CRP positivity rate was significantly higher in the HCC group (64.15%) compared with that in the LC group (37.97%) (P<0.01). These results demonstrate the association of HCC with combined detection of LS and serum CRP.

In conclusion, the combined detection of LS and serum CRP may complement the measurement of AFP level in the diagnosis of HBV-related HCC, facilitate the identification of patients with AFP-negative HCC, and help distinguish HCC from LC.

 Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (grant no. 81460301), the Natural Science Foundation of Ningxia (grant nos. NZ09115 and NZ11199), and the Scientific and Technological Foundation of Ningxia and Chinese Foundation for Hepatitis Wang Bao-En Liver Fibrosis Fund (grant no. xjs).

 Abbreviations HCC

hepatocellular carcinoma

 HBV

hepatitis B virus

 CRP

C-reactive protein

 LSM

liver stiffness measure

 CHB

chronic hepatitis B

 References El-SeragHBEpidemiology of viral hepatitis and hepatocellular carcinomaGastroenterology14212641273201210.1053/j.gastro.2011.12.06122537432 LukJMLiuAMProteomics of hepatocellular carcinoma in Chinese patientsOMICS15261266201110.1089/omi.2010.009921348761 LinCLKaoJHRisk Stratification for hepatitis B virus related hepatocellular carcinomaJ Gastroenterol Hepatol281017201310.1111/jgh.1201023094699 GaoYJiangQZhouXDingBWangRZhaoGChenYHBV infection and familial aggregation of liver cancer: An analysis of case-control family studyCancer Causes Control15845850200410.1023/B:CACO.0000043435.59195.3c15456998 SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin.631130201310.3322/caac.2116623335087 CabreraRFitianAIAraratMXuYBruskoTWasserfallCAtkinsonMALiuCNelsonDRSerum levels of soluble CD25 as a marker for hepatocellular carcinomaOncol Lett4840846201223205111 MasuzakiRKarpSJOmataMNew serum markers of hepatocellular carcinomaSemin Oncol39434439201210.1053/j.seminoncol.2012.05.00922846860 MarcellinPZiolMBedossaPDouvinCPouponRde LédinghenVBeaugrandMNon-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis BLiver Int29242247200910.1111/j.1478-3231.2008.01802.x18637064 do KimYKimSUAhnSHParkJYLeeJMParkYNYoonKTPaikYHLeeKSChonCYUsefulness of FibroScan for detection of early compensated liver cirrhosisin chronic hepatitis BDig Dis Sci5417581763200910.1007/s10620-008-0541-219005758 ChanHLWongGLChoiPCChanAWChimAMYiuKKChanFKSungJJWongVWAlanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis BJ Viral Hepat163644200910.1111/j.1365-2893.2008.01037.x18673426 VizzuttiFIArenaURomanelliRGRegaLFoschiMColagrandeSPetrarcaAMoscarellaSBelliGZignegoALLiver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosisHepatolog4512901297200710.1002/hep.21665 CesconMColecchiaACucchettiAPeriEMontroneLErcolaniGFestiDPinnaADValue of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinomaAnn Surg256706712discussion 712–713201210.1097/SLA.0b013e3182724ce823095613 MasuzakiRTateishiRYoshidaHGotoESatoTOhkiTImamuraJGotoTKanaiFKatoNProspective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastographyHepatology4919541961200910.1002/hep.2287019434742 JungKSKimSUAhnSHParkYNdo KimYParkJYChonCYChoiEHHanKHRisk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)Hepatology53885894201110.1002/hep.2412121319193 FungJLaiCLSetoWKWongDKYuenMFPrognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis BJ Viral Hepat18738744201110.1111/j.1365-2893.2010.01355.x20659306 ChonYEJungESParkJYdo KimYAhnSHHanKHChonCYJungKSKimSUThe accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis BJ Clin Gastroenterol.46518525201210.1097/MCG.0b013e31825079f122688146 ShameemMBhargavaRAhmadZSaadTFatimaNMalikAAssociation between serum C-reactive protein levels and other important predictive markers of outcome in COPDActa Med Iran491820201121425065 TasxiCBalkanAKaradurmusNInalSKilicSOzkanMBilgicHEkizKThe importance of serum procalcitonin levels in patients with chronic obstructive pulmonary disease exacerbationsTurk J Med Sci381391442008 Garcia-RioFMiravitllesMSorianoJBMuñozLDuran-TauleriaESánchezGSobradilloVAncocheaJEPI-SCAN Steering Committee: Systemic inflammation in chronic obstructive pulmonary disease: A population-based studyRespir Res1163200810.1186/1465-9921-11-63 PeisajovichAMarnellLMoldCDu ClosTWC-reactive protein at the interface between innate immunity and inflammationExpert Rev Clin Immunol4379390200810.1586/1744666X.4.3.37920476927 DinarelloCAThe acute phase responseCecil Textbook of Medicine20thBennettJCPlumFWB Saunders Co.153515371996 AndreozziPViscogliosiGColellaFSubicMCiprianiEMariglianoBVerrusioWServelloAEttorreEMariglianoVPredictors of liver fibrosis in patients with non-alcoholic fatty liver disease. The role of metabolic syndrome, insulin-resistance and inflammationRecenti Prog Med103570574201223258240 MaLNLiuXYLuoXHuYCLiuSWTangYYPanJLDingXCSerum high-sensitivity C-reactive protein are associated with HBV replication, liver damage and fibrosis in patients with chronic hepatitis BHepatogastroenterology62368372201525916065 AttaMCabralMSantosGParanáRAttaAInflammation biomarkers in chronic hepatitis C: Association with liver histopathology, HCV genotype and cryoglobulinemiaInflamm Res6111011106201210.1007/s00011-012-0502-222718074 SjöwallCICardellKBoströmEABokarewaMIEnocssonHEkstedtMLindvallLFrydénAAlmerSHigh prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammationHum Immunol73382388201210.1016/j.humimm.2012.01.00922333691 NishikawaHArimotoAWakasaTKitaRKimuraTOsakiYPre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinomaAnticancer research3311811188201323482800 ChenWWangJBAbnetCCDawseySMFanJHYinLYYinJTaylorPRQiaoYLFreedmanNDAssociation between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: A nested case-control studyCancer Epidemiol Biomarkers Prev24386392201510.1158/1055-9965.EPI-14-103825613115 ZhaoXLuoJLiBLiuSLiDThe association between preoperative serum C-reactive protein and hepatocellular carcinoma recurrence in patients with chronic hepatitis B virus (HBV) infection-a retrospective studyPLoS One10e0116909201510.1371/journal.pone.011690925602444 Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association: The guideline of prevention and treatment for chronic hepatitis B (2010 version)Chin J Hepatol1913242011(In Chinese)

LSM values and serum hs-CRP levels (mean ± SD).

Groups No. hs-CRP (mg/l) LSM values (kPa)
Healthy 50 0.78±1.07 4.25±0.74
LC 89 9.47±19.56 27.81±18.46
HCC 67 30.78±15.17 39.72±29.05
t-test −0.964 −1.735
P-value     0.0337     0.0093

LSM, liver stiffness measurement; LC, liver cirrhosis; hs-CRP, high-sensitivity C-reactive protein; HCC, hepatocellular carcinoma.

LSM values and serum hs-CRP levels in AFP-positive and -negative patients (mean ± SD).

AFP status No. hs-CRP (mg/ml) LSM values (kPa)
Positive 35 13.58±27.16 48.95±28.59
Negative 32 8.66±17.72 28.64±26.83
t-test 0.815 1.706
P-value 0.419 1.104

LSM, liver stiffness measurement; AFP, α-fetoprotein; hs-CRP, high-sensitivity C-reactive protein.

Proportion analysis of HCC, LSM grade and serum hs-CRP positivity rate.

LC group HCC group
LSM grade (kPa) Case (no.) CRP+, no. (%) CRP−, no. (%) CRP+, no. (%) CRP−, no. (%)
17.5–22.5 0 0/0 (0.0) 0/0 (0.0) 0/0 (0.0) 0/0 (0.0)
22.6–27.5 24 0/10 (0.0) 10/10 (100.0) 0/14 (0.0) 14/14 (100.0)
>27.6 132 30/79 (37.97) 49/79 (62.03) 34/53 (64.15) 19/53 (35.85)
χ2 test 8.847 24.89
P-value 0.003     0.000

LSM, liver stiffness measurement; hs-CRP, high-sensitivity C-reactive protein; HCC, hepatocellular carcinoma.